S. Korea has just approved a Phase 3 trial of the COVID nanoparticle vaccine we reported last year in Cell: cell.com/cell/fulltext/… All Phase 1/2 trial participants induced neutralizing antibodies. King Lab The Veesler Lab UW Medicine reuters.com/world/asia-pac…

Our RBD nanoparticle vaccine has now entered Phase III clinical trials. We remain hopeful that our work will meaningfully contribute to fighting the pandemic. Huge team effort with The Veesler Lab Gates Foundation CEPI skbioscience GSK. bit.ly/3jsd4OG

Congratulations to my former PI and mentor Barney Graham, MD, PhD on this amazing honor from TIME & best of luck during retirement! time.com/collection/100…

New preprint! We came up with 2 methods to design de novo scaffold proteins to hold arbitrary functional motifs: hallucination (optimizing a seq against predictions of RoseTTAFold (RF)) and inpainting (recover masked regions of seq+struc.) 1/n biorxiv.org/content/10.110…

My time at the King Lab and Institute for Protein Design has come to an end, and it was a fantastic experience. I'm starting at @icosavax this week for continued work on vaccine design, super excited!

Delighted to share our manuscript describing the structure and antigenic properties of the Nipah virus attachment glycoprotein (G). Led by 只不过肚子有点软 HHMI NIAID News Victoria McGovern 🇺🇸🇬🇷🇮🇪🏴‍☠️ 1/13 science.org/doi/10.1126/sc…

Our work on the stabilization of flu NA is officially published in Nature Communications! Large congrats and thanks to Julia Lederhofer, @kanekiyom, King Lab, The Veesler Lab, Oliver Acton, Barney Graham, MD, PhD and many more

What a special moment: the #COVID19 vaccine we designed with Lexi Walls King Lab has met its primary endpoints in the phase 3 clinical trial run by SK bioscience!!! HHMI Institute for Protein Design UW Biochemistry 1/4 newsroom.uw.edu/news/uw-medici…

I want to let you know that we have a paper out as accelerated article preview in Nature about how vaccination combined with #Omicron/BA.1 infection hybrid immunity enhanced the neutralizing immune response to other variants, including BA.2: nature.com/articles/s4158…

We analyzed human plasma, mucosal and memory antibody responses against #SARSCoV2 and found a pan-variant neutralizing antibody! Led by Young-jun Park Dora Pinto Lexi Walls Zhuoming(Joemin) Liu Collab. with Davide Corti HHMI Vir Biotechnology 1/24 biorxiv.org/content/10.110…

SKYCovione (the #COVID19 vaccine we developed with King Lab) has been approved for use in South Korea. Thank you so much to all our collaborators and especially SK Bioscience for bringing this vaccine to the finish line! HHMI UW Biochemistry skbioscience.co.kr/en/news/news_0…

SKYCovione, a COVID-19 vaccine developed by King Lab & The Veesler Lab, has just won full approval abroad!🇰🇷This protein-based vaccine outperforms Oxford/AstraZeneca's and does not require freezing. It is our first designed protein medicine. Learn more: ipd.uw.edu/2022/06/covid-…

Happy to release the “degreaser” into the world! If you need your proteins to secrete, perhaps this is something for you. Checkout the preprint! biorxiv.org/content/10.110…

Our paper on a (mosaic) nanoparticle vaccine against hepatitis C virus (#HCV) is just out in Nature Communications nature.com/articles/s4146… Institute for Immunology and infectious Diseases 1/6

Quinton's paper on designed constitutively active cGAS is out today! cGAS is a really neat enzyme and we found that if you stabilize the active conformation through mutation, you no longer need the dsDNA ligand for activity. Read more here: tinyurl.com/yc35ees5

Positive Phase I results for @icosavax's bivalent RSV/HMPV vaccine candidate displaying prefusion F-based antigens on their protein nanoparticles ir.icosavax.com/news-releases/…

Regulators in the UK have granted full approval to SKYCovione, the computationally designed COVID-19 vaccine pioneered by King Lab and The Veesler Lab | UW Medicine gov.uk/government/new…